Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who ...

The target of blood pressure control in hypertensive patients with diabetes mellitus should be <130/80 mm Hg. (Recommendation grade: B, Consensus, Evidence level: I) The target home blood pressure ...

Blockade of the renin–angiotensin system has beneficial effects in patients with diabetic nephropathy; however, this treatment can induce aldosterone breakthrough and thus become ineffective. New data ...

A health explainer details how specific foods and beverages interact with blood pressure therapy, emphasizing safety ...

The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting ...

Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of ...

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular ...

For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a ...